Riboxin [Inosine]

Riboxin Inosine Pharmacotherapeutic group:

metabolic agent.

KODATH: [С01ЕВ].

Pharmacological properties:

Riboxin is a derivative (nucleoside) of purine – the precursor of ATP adenosine triphosphate. It belongs to the group of drugs that stimulate metabolic processes. It has antihypoxic and antiarrhythmic effects. Increases the energy balance of the myocardium, improves coronary circulation, prevents the effects of intraoperative renal ischemia. He is directly involved in glucose metabolism and contributes to the activation of metabolism in hypoxic conditions and in the absence of ATP.

It activates the metabolism of pyruvic acid to ensure the normal process of tissue respiration, and also contributes to the activation of xanthine dehydrogenase. Stimulates the synthesis of nucleotides, enhances the activity of certain enzymes of the Krebs cycle. Penetrating into the cells, it has a positive effect on metabolic processes in the myocardium – it increases the strength of the heart contractions and contributes to a more complete relaxation of the myocardium in diastole, as a result of which the stroke volume increases. The mechanism of antiarrhythmic action is not fully understood.

Reduces platelet aggregation, activates tissue regeneration (especially the myocardium and gastrointestinal mucosa).

Pharmacokinetics

Metabolized in the liver with the formation of glucuronic acid and its subsequent oxidation. In small quantities excreted in the urine.